Please assess the completion status of the following clinical trial:

Trial Title: Dietary Histone Deacetylase Inhibitors (HDAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* age: 20 and older~* body mass index 19-30 kg/sq m~* willingness to maintain normal exercise and activity patterns~* willingness to avoid cruciferous vegetables and garlic and related foods (onion etc.) 1 week before and 2 weeks during the trial for a total of 3 weeks~Exclusion criteria:~* tobacco use within the past three months~* engaging in aerobic activity more than 6 hours per week~* being vegetarian or having other restrictive dietary requirements~* consuming \>3 alcoholic beverages/day or \>10 per week~* having history of diabetes or uremia or other known metabolic disease~* participating in another dietary study within the past three months~* for women, being pregnant or breastfeeding~* gastrointestinal diseases that could increase gut permeability, including Crohn's disease, ulcerative colitis, gastritis~* taking dietary supplements other than those given in the study~* abnormal liver function, CBC, or thyroid values~* individuals taking any drug or medication, prescription or over the counter, including Isoniazid, Saquinavir, Warfarin, Cyclosporine, Acetaminophen, Oxazepam, medications used for HIV/ AIDS, blood clotting, birth control pills, fish oil and medications metabolized by CYPs (CYP1A2, CYP2E1 and CYP3A4) during the dosing period of 1 week and 48 h prior to and after dosing. Exceptions may be made by the study MD and the PI if in their opinion a medication will not interfere with the scientific validity of the study. The study MD will evaluate a medication on a case-by-case basis to determine that efficacy and safety are not adversely affected.~* Individuals who are known to have problems with blood clotting or increased bleeding, including hemophiliacs or anyone recently undergoing or recovering from a surgical procedure.~* soy or garlic allergy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BSE placebo & garlic oil placebo (Type: PLACEBO_COMPARATOR): Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
- garlic oil plus BSE placebo (Type: ACTIVE_COMPARATOR): one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
- BSE plus garlic oil placebo (Type: ACTIVE_COMPARATOR): two BSE capsules plus one garlic oil placebo capsule per day for seven days
- BSE & Garlic Oil (Type: ACTIVE_COMPARATOR): two BSE and one garlic oil capsule per day for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).